Overland Pharmaceuticals has announced its official launch with a mission to bring innovative medicines to underserved patients in Asia and around the world.
The global investment firm Hillhouse Capital is backing Overland to build a fully-integrated biopharmaceutical company through collaborations in certain disease areas.
"Advancing breakthroughs in biomedicine such as antibody drug conjugates, cell therapy, RNAi and more"Overland is staffed with highly experienced biotech leaders with a strong track record of achieving drug approvals in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze